Mitochondrial diseases, particularly those linked to complex I defects, currently have no cure, highlighting the need for better drug discovery methods.
*Induced pluripotent stem cells (iPSCs) can be genetically modified using CRISPR-Cas9, creating models like the NDUFS4 knockout (KO) that exhibit significant metabolic changes linked to mitochondrial dysfunction.
*Metabolomic profiling of NDUFS4 KO iPSCs revealed an increased NADH/NAD ratio, and treatment with β-lapachone improved the redox state, emphasizing the potential of iPSCs for developing new therapies for mitochondrial disorders.*